The European Commission extended the Marketing Authorisation for Vueway® (gadopiclenol) in the European Union for use in pediatric patients under 2 years of age
Expanded EU approval reflects positive benefit-risk ratio of Vueway® in children from birth MILAN, Jan. 27, 2026 /PRNewswire/ — Bracco Imaging S.p.A.,…
